FDA 483 - Andrew M. Schneider, MD - November 07, 2025

An FDA inspection of Andrew M. Schneider, MD, a clinical investigator in Tamarac, FL, revealed one observation related to the conduct of a clinical investigation. The firm failed to conduct an investigation in accordance with the signed statement of investigator and investigational plan. Specifically, required documentation was not submitted for a randomized subject per protocol and inclusion criteria.